Airway Complication of AnesthesiaADEPT1NCT03664700
Observational Study of the LMA Protector
An observational study of Airway Complication of Anesthesia, run by Oxford University Hospitals NHS Trust at 5 sites in United Kingdom.
Trial summary
The investigators want to investigate the user friendliness, and performance of the LMA Protector. The principal research question is to assess the overall performance of the LMA Protector. The investigators are merely making observations related to use of the device during clinical practice. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Airway Complication of Anesthesia
- What is being tested?
- LMA Protector
- Type of treatment
- Medical device
- How many people
- 112 participants
- Where
- 5 sitesUnited Kingdom
- Study dates
- 5 Nov 2019to 1 Aug 2021
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients undergoing operation under general anaesthesia with a supraglottic airway device
Who may be able to join
- Adult participants who are having a general anaesthetic.
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- ASA 1 - 3 category patients
- Elective operations
- Urgent operations
- Patients suitable for an SAD based on patient and operation factors.
Who cannot join
- The participant may not enter the study if ANY of the following apply:
- Refusal of consent
- Age less than 18 years
- Require intubation for the operation
- Risk of regurgitation
- ASA 4 and above
- Mouth opening less than 2.5cm Require awake intubation
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United Kingdom5 sites
Royal United Hospital
Bath
Aneurin Bevan University Health Board
Cardiff
Nothampton General Hospital
Northampton
Oxford University Hospitals
Oxford
Royal Berkshire Hospital
Reading
About this study
Official title: ADEPT 1 - Observational Study of the LMA Protector
The investigators want to investigate the user friendliness, and performance of the LMA Protector. The principal research question is to assess the overall performance of the LMA Protector. The investigators are merely making observations related to use of the device during clinical practice.
Read the detailed description
There is a lack of research data on regarding the use of the LMA Protector. There is no regulatory requirement to collect or publish patient data on any device, either before CE marking or after. These devices are freely purchased and used.
There is, however, a professional duty to know that a device conforms to established norms for use. These norms are not official standards but rather, reference data against which a device can be clinically judged. Therefore, a device that is easy to insert but has a low 'leak pressure' (see above) is different from one that is more difficult to insert but as a high leak pressure. It is not that one is 'better' than the other, but rather that the data help create a 'usability profile' of the device which can be useful when making a clinical selection for the device.
Preoperative assessment:
During the preoperative visit, patient information leaflet will be given to the patients meeting the eligibility criteria.
Wherever possible, suitable patients will be identified in the preoperative assessment clinic and the information leaflet given. The patients will be given adequate time to read this information and any queries will be answered before being asked to sign a consent form. A detailed airway assessment will be performed by one of the investigators and documented on the study proforma.
Induction of anaesthesia:
On arrival in the anaesthetic room patients will be monitored with pulse oximetry, electrocardiography and invasive or non-invasive blood pressure measurements. After intravenous access is secured and the pre-surgical checklist completed, all patients will be pre-oxygenated using a facemask to achieve end tidal oxygen concentration of at least 80%. A 'sniffing' position of the head and neck and a 20 degree head-up bed tilt will be used for pre-oxygenation. General anaesthesia will be induced intravenously. After induction of anaesthesia, facemask ventilation will be commenced and anaesthesia maintained with an inhalational anaesthetic agent in oxygen or with total intravenous anaesthesia. The volatile agent's (anesthetic gases) concentration of 1 MAC adjusted for the patient's age will be achieved and maintained. This is normal process of anaesthesia applicable for all patients irrespective of participation in the study.
Supraglottic airway device (SAD) insertion:
Once deep plane of anaesthesia is confirmed, with the absence of movement to jaw thrust stimulation the SAD (LMA protector) will be inserted. The size of the device will be based on the manufacturer's recommendations for the body weight. The breathing system will be connected to the device. Ventilation of the lungs will be then confirmed by observing adequate bilateral chest inflation and square end-tidal capnogram wave with positive pressure ventilation. Adequate ventilation will be recorded if three tests are passed: 1) adequate chest movement, 2) an expired tidal volume of at least 7 ml/kg and 3) stable oxygenation. Time would continue until LMA® ProtectorTM inserted successfully. If it is not possible to insert the device or ventilate through it, two more attempts at placement of the device will be allowed. If placement has failed after two further attempts, the study will be abandoned and the other device will be used. If this fails on first attempt a different LMA or tracheal tube will be used as appropriate.
Maintenance of anaesthesia and recovery
The main interventions refer to the insertion of the airway device into the patient to obtain a airway and allow the conduct of the anaesthetic and therefore the surgery. However, if there are problems with the device and the airway obtained is suboptimal then the below interventions are allowed (which will be noted in the data collection form):
- Neck extension - move patient's neck upward
- Neck flexion - move patient's neck downward
- Chin lift - manoeuvre to open the airway
- Jaw thrust - manoeuvre to open the airway
- Reposition of the device At the end of operation, anaesthetic agents will be discontinued while the device is left in place. The device will be removed after the patient has regained consciousness, and has responded to verbal command to open the mouth. Any complications that occur during the use of the device will be recorded.
Postoperative assessment Postoperatively in recovery or on the ward, the investigators will visit each patient and determine whether the following airway complications are present after surgery: sore throat (constant pain, independent of swallowing), dysphagia (difficulty in, or pain provoked by, swallowing), sore jaw, dysphonia (difficulty in, or pain on, speaking), numbness of the tongue or the oropharynx, ear pain, neck or mouth ache, hearing changes. Each complication will be graded as none, mild, moderate or severe. The same questions will be asked 24-48 hours later.
First visit During the first visit by the anaesthetist to the participant, at the anaesthetist's earliest opportunity, either in the recovery area or on the ward, the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe.
- Vomiting
- Lip or tongue swelling
- Hearing changes
- Ear pain
- Sore throat
- Pain on swallowing
- Jaw pain
- Neck or mouth ache
- Pain on speaking
- Numbness of the tongue
Second visit (or telephone consultation) During the second visit 24-48 hours post-operatively on the ward or via telephone the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe.
- Vomiting
- Lip or tongue swelling
- Hearing changes
- Ear pain
- Sore throat
- Pain on swallowing
- Jaw pain
- Neck or mouth ache
- Pain on speaking
- Numbness of the tongue
- Conditions
- Airway Complication of Anesthesia
- Being tested
- LMA Protector
- Keywords
- Supraglottic airway device, LMA Protector
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LMA ProtectorDevice
The LMA Protector will be inserted when a supraglottic device is needed
| Study group | Role | What they receive |
|---|---|---|
| LMA Protector | The LMA Protector will be used Receives: Device: LMA Protector |
What is being measured
The primary outcome is the main question the study is designed to answer.
First go Insertion Success Rate
Whether insertion during first go was successful or not
Measured: Day 1
First go Successful Ventilation Rate
Whether ventilation during first go was successful or not
Measured: Day 1
Number of Participants With Complication Free Insertions
Number of participants with complication free insertions divided by total number of participants
Measured: Day 1
Secondary outcomes (9)
Time to First Square Capnography Waveform
Record time in seconds of time to first capnography trace
Measured: Day 1
Lowest Oxygen Saturation Level
Record of lowest oxygen saturation reading across all participants
Measured: Day 1
Interventions Needed to Ensure Airway Patency
Collect number of predefined interventions needed to keep airway patent
Measured: Day 1
Number of Participants With Visible Chest Movement
The success of ventilation will depend on whether there was visible chest movement
Measured: Day 1
Number of Participants With Adequate Tidal Volume at Attempt of Ventilation
The success of ventilation will depend on whether there was tidal volume > 7ml/kg
Measured: Day 1
Number of Participants With Stable Oxygen Saturations
The success of ventilation will depend on whether there was stable SpO2
Measured: Day 1
Number of Participants With Square Capnography Trace
The success of ventilation will depend on whether there was square capnography trace
Measured: Day 1
Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal
Collect number of pre-defined complications of device usage
Measured: Day 1
Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal
Collect number of pre-defined complications of device usage. Secondary complication where asked about on Day 2 to ensure patients had recovered from the effects of the anaesthetic and are able to report any complications.
Measured: Day 2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2018
- Study start5 Nov 2019
- Primary completion1 Aug 2021
- Study completion1 Aug 2021
Why it stopped: Due to problems caused by the COVID-19 pandemic
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Airway Complication of AnesthesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 112 participants (actual)
Sponsor and investigators
- Lead sponsor
- Oxford University Hospitals NHS Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Royal United Hospital Bath NHS Trust, Royal Berkshire NHS Foundation Trust, Northampton General Hospital NHS Trust, University Hospital of Wales
- Responsible party
- Principal investigator, Vassilis Athanassoglou, Oxford University Hospitals NHS Trust
- Investigators
- Vassilis Athanassoglou, Principal investigator, Oxford University Hospitals NHS Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03664700
- Sponsor's protocol ID
- 1338
- Acronym
- ADEPT1
- Status last verified
- Jan 2025
- First submitted
- 26 Jul 2018
- Last updated
- 14 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be collected prospectively on data collection sheets completed by the anaesthetist / investigator during anaesthesia. Each site will manage their own data set and the data will be pooled at the end of the recruitment phase across all sites. Data will be sent from sites to the lead study team only at the end of the data collection. Consent form and initial data collection forms will be filed in the master folder and kept locked in the dedicated research locker in the department. The PI at each site will have access to this log. Each site will assign a study ID for each participant and a record of these IDs will be kept in the site file. Only anonymised data will be sent from each trust to the main study team. No personal data will be sent to the coordinating centre.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ADEPT 1 - Observational Study of the LMA Protector
- ClinicalTrials.gov ID
- NCT03664700
- Acronym / sponsor ID
- ADEPT1 / 1338
- Conditions
- Airway Complication of Anesthesia
- Keywords
- Supraglottic airway device, LMA Protector
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Due to problems caused by the COVID-19 pandemic
- Enrolment
- 112 participants (actual)
- Lead sponsor
- Oxford University Hospitals NHS TrustUniversity, hospital or other
- Collaborators
- Royal United Hospital Bath NHS Trust, Royal Berkshire NHS Foundation Trust, Northampton General Hospital NHS Trust, University Hospital of Wales
- Study start
- 5 Nov 2019 (actual)
- Primary completion
- 1 Aug 2021 (actual)
- Study completion
- 1 Aug 2021 (actual)
- First posted
- 10 Sep 2018 (actual)
- Results
- Posted 14 Jan 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators want to investigate the user friendliness, and performance of the LMA Protector. The principal research question is to assess the overall performance of the LMA Protector. The investigators are merely making observations related to use of the device during clinical practice.
Detailed description
There is a lack of research data on regarding the use of the LMA Protector. There is no regulatory requirement to collect or publish patient data on any device, either before CE marking or after. These devices are freely purchased and used.
There is, however, a professional duty to know that a device conforms to established norms for use. These norms are not official standards but rather, reference data against which a device can be clinically judged. Therefore, a device that is easy to insert but has a low 'leak pressure' (see above) is different from one that is more difficult to insert but as a high leak pressure. It is not that one is 'better' than the other, but rather that the data help create a 'usability profile' of the device which can be useful when making a clinical selection for the device.
Preoperative assessment:
During the preoperative visit, patient information leaflet will be given to the patients meeting the eligibility criteria.
Wherever possible, suitable patients will be identified in the preoperative assessment clinic and the information leaflet given. The patients will be given adequate time to read this information and any queries will be answered before being asked to sign a consent form. A detailed airway assessment will be performed by one of the investigators and documented on the study proforma.
Induction of anaesthesia:
On arrival in the anaesthetic room patients will be monitored with pulse oximetry, electrocardiography and invasive or non-invasive blood pressure measurements. After intravenous access is secured and the pre-surgical checklist completed, all patients will be pre-oxygenated using a facemask to achieve end tidal oxygen concentration of at least 80%. A 'sniffing' position of the head and neck and a 20 degree head-up bed tilt will be used for pre-oxygenation. General anaesthesia will be induced intravenously. After induction of anaesthesia, facemask ventilation will be commenced and anaesthesia maintained with an inhalational anaesthetic agent in oxygen or with total intravenous anaesthesia. The volatile agent's (anesthetic gases) concentration of 1 MAC adjusted for the patient's age will be achieved and maintained. This is normal process of anaesthesia applicable for all patients irrespective of participation in the study.
Supraglottic airway device (SAD) insertion:
Once deep plane of anaesthesia is confirmed, with the absence of movement to jaw thrust stimulation the SAD (LMA protector) will be inserted. The size of the device will be based on the manufacturer's recommendations for the body weight. The breathing system will be connected to the device. Ventilation of the lungs will be then confirmed by observing adequate bilateral chest inflation and square end-tidal capnogram wave with positive pressure ventilation. Adequate ventilation will be recorded if three tests are passed: 1) adequate chest movement, 2) an expired tidal volume of at least 7 ml/kg and 3) stable oxygenation. Time would continue until LMA® ProtectorTM inserted successfully. If it is not possible to insert the device or ventilate through it, two more attempts at placement of the device will be allowed. If placement has failed after two further attempts, the study will be abandoned and the other device will be used. If this fails on first attempt a different LMA or tracheal tube will be used as appropriate.
Maintenance of anaesthesia and recovery
The main interventions refer to the insertion of the airway device into the patient to obtain a airway and allow the conduct of the anaesthetic and therefore the surgery. However, if there are problems with the device and the airway obtained is suboptimal then the below interventions are allowed (which will be noted in the data collection form):
- Neck extension - move patient's neck upward
- Neck flexion - move patient's neck downward
- Chin lift - manoeuvre to open the airway
- Jaw thrust - manoeuvre to open the airway
- Reposition of the device At the end of operation, anaesthetic agents will be discontinued while the device is left in place. The device will be removed after the patient has regained consciousness, and has responded to verbal command to open the mouth. Any complications that occur during the use of the device will be recorded.
Postoperative assessment Postoperatively in recovery or on the ward, the investigators will visit each patient and determine whether the following airway complications are present after surgery: sore throat (constant pain, independent of swallowing), dysphagia (difficulty in, or pain provoked by, swallowing), sore jaw, dysphonia (difficulty in, or pain on, speaking), numbness of the tongue or the oropharynx, ear pain, neck or mouth ache, hearing changes. Each complication will be graded as none, mild, moderate or severe. The same questions will be asked 24-48 hours later.
First visit During the first visit by the anaesthetist to the participant, at the anaesthetist's earliest opportunity, either in the recovery area or on the ward, the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe.
- Vomiting
- Lip or tongue swelling
- Hearing changes
- Ear pain
- Sore throat
- Pain on swallowing
- Jaw pain
- Neck or mouth ache
- Pain on speaking
- Numbness of the tongue
Second visit (or telephone consultation) During the second visit 24-48 hours post-operatively on the ward or via telephone the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe.
- Vomiting
- Lip or tongue swelling
- Hearing changes
- Ear pain
- Sore throat
- Pain on swallowing
- Jaw pain
- Neck or mouth ache
- Pain on speaking
- Numbness of the tongue
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| LMA Protector | – | Device: LMA ProtectorThe LMA Protector will be used |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing operation under general anaesthesia with a supraglottic airway device
Key inclusion criteria (7 listed)
- Adult participants who are having a general anaesthetic.
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- ASA 1 - 3 category patients
- Elective operations
Key exclusion criteria (7 listed)
- Refusal of consent
- Age less than 18 years
- Require intubation for the operation
- Risk of regurgitation
- ASA 4 and above
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LMA ProtectorThe LMA Protector will be inserted when a supraglottic device is needed | Device | LMA Protector |
Primary outcome
First go Insertion Success Rate
Time frame: Day 1
Whether insertion during first go was successful or not
First go Successful Ventilation Rate
Time frame: Day 1
Whether ventilation during first go was successful or not
Number of Participants With Complication Free Insertions
Time frame: Day 1
Number of participants with complication free insertions divided by total number of participants
9 secondary outcomes
Time to First Square Capnography Waveform
Time frame: Day 1
Lowest Oxygen Saturation Level
Time frame: Day 1
Interventions Needed to Ensure Airway Patency
Time frame: Day 1
Number of Participants With Visible Chest Movement
Time frame: Day 1
Number of Participants With Adequate Tidal Volume at Attempt of Ventilation
Time frame: Day 1
Number of Participants With Stable Oxygen Saturations
Time frame: Day 1
Number of Participants With Square Capnography Trace
Time frame: Day 1
Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal
Time frame: Day 1
Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal
Time frame: Day 2
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No. Data will be collected prospectively on data collection sheets completed by the anaesthetist / investigator during anaesthesia. Each site will manage their own data set and the data will be pooled at the end of the recruitment phase across all sites. Data will be sent from sites to the lead study team only at the end of the data collection. Consent form and initial data collection forms will be filed in the master folder and kept locked in the dedicated research locker in the department. The PI at each site will have access to this log. Each site will assign a study ID for each participant and a record of these IDs will be kept in the site file. Only anonymised data will be sent from each trust to the main study team. No personal data will be sent to the coordinating centre.
Related trials for Airway Complication of Anesthesia
Not yet recruitingPhase 3
Effect of Nebulized Lignocaine on Emergence Agitation After Sevoflurane Anesthesia in Pediatric Patients Undergoing Tonsillectomy
Emergence Agitation, Emergence Delirium
Not yet recruiting
Postoperative Pulmonary Complications After Use of Supraglottic Airway Devices and Neuromuscular Blockade
Postoperative Pulmonary Complications
RecruitingObservational study
Comparison of Acute Airway/Respiratory Complications and Intervention Requirements in Extubations Performed During On-Hours Versus Off-Hours
Extubation Failures, Extubation
Not yet recruitingObservational study
Effect of Night Shift Versus Daytime Duty on Tracheal Intubation Complications and Duration in Surgical Patients
Airway Management, Tracheal Intubation
Recruiting
Effect of Endotracheal Tube Cuff Pressure Management on Postoperative Sore Throat in Pediatric Laparoscopic Appendectomy
Appendicitis Acute, Postoperative Sore Throat, Cough, Hoarseness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vassilis Athanassoglou principal investigator
Oxford University Hospitals NHS Trust
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Airway Complication of Anesthesia, run by Oxford University Hospitals NHS Trust at 5 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
First go Insertion Success Rate (time frame: Day 1). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2025.